KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Edwards Lifesciences (EW) Tax Provisions (2016 - 2025)

Edwards Lifesciences has reported Tax Provisions over the past 17 years, most recently at $26.2 million for Q4 2025.

  • Quarterly results put Tax Provisions at $26.2 million for Q4 2025, down 41.91% from a year ago — trailing twelve months through Dec 2025 was $216.9 million (up 42.6% YoY), and the annual figure for FY2025 was $216.9 million, up 42.6%.
  • Tax Provisions for Q4 2025 was $26.2 million at Edwards Lifesciences, down from $56.1 million in the prior quarter.
  • Over the last five years, Tax Provisions for EW hit a ceiling of $70.3 million in Q1 2025 and a floor of $10.9 million in Q4 2022.
  • Median Tax Provisions over the past 5 years was $50.9 million (2021), compared with a mean of $46.5 million.
  • Biggest five-year swings in Tax Provisions: crashed 73.41% in 2022 and later skyrocketed 221.5% in 2025.
  • Edwards Lifesciences' Tax Provisions stood at $41.0 million in 2021, then crashed by 73.41% to $10.9 million in 2022, then surged by 212.84% to $34.1 million in 2023, then skyrocketed by 32.26% to $45.1 million in 2024, then tumbled by 41.91% to $26.2 million in 2025.
  • The last three reported values for Tax Provisions were $26.2 million (Q4 2025), $56.1 million (Q3 2025), and $64.3 million (Q2 2025) per Business Quant data.